Sarepta Therapeutics, Inc. (SRPT) Stock Price & How to Invest

Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease. Its portfolio has two pillars: Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for DMD delivered with the AAVrh74 viral vector, and an older RNA-based exon-skipping franchise (Exondys 51, Vyondys 53, Amondys 45) that treats subsets of patients by helping cells skip faulty sections of the dystrophin gene. Roche holds ex-US commercialization rights to Elevidys, which produces meaningful licensing and royalty revenue for Sarepta. The company reiterated 2026 net product revenue guidance of roughly $1.2 billion to $1.4 billion.

The investment picture in mid-2026 is defined by a severe safety and regulatory shock. In 2025 Sarepta reported multiple patient deaths from acute liver failure tied to its AAVrh74 gene-therapy vector, the FDA added a boxed warning, revoked the platform technology designation, requested a shipment halt, and placed a related trial on clinical hold. The company cut about 36 percent of its workforce (roughly 500 employees) and restructured to target around $400 million in annualized savings and self-fund its pipeline. Market capitalization fell from over $11 billion in early 2025 to roughly $2 billion by mid-2026, so the stock now reflects deep uncertainty about Elevidys adoption alongside a still-profitable base RNA business.

The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences, several of which could reach the market in 2026-2027. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sarepta Therapeutics, Inc.'s investor relations page or your broker.

• Market cap: ~$2.1B
• 2026 revenue guidance: ~$1.2B-$1.4B
• Cash & investments: ~$748M
• 2026 non-GAAP expense outlook: ~$800M-$900M
• 2025 base-business cash flow: ~$330M+
• Workforce reduction: ~36% (~500 roles)

SRPT's market cap fell roughly 80 percent from over $11 billion in early 2025 to around $2 billion by mid-2026 as the Elevidys safety events reset expectations. The company remains a real revenue-generating biotech with reiterated 2026 net product revenue guidance of roughly $1.2 billion to $1.4 billion and a cash cushion. Valuation now reflects deep uncertainty about gene-therapy adoption rather than a going-concern question about the base RNA business.

There are three common ways to get SRPT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SRPT sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SRPT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

SRPT is a real revenue-generating DMD franchise trading at a fraction of its former value, where the durability of Elevidys after safety and label setbacks is the central question.

Whether SRPT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SRPT a buy?, and where the stock could go from here in the SRPT stock forecast.

For income investors, whether SRPT pays a dividend and how the payout looks is covered in does SRPT pay a dividend?